Patents by Inventor Weilan Ye

Weilan Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized anti-EGFL7 antibodies and methods using same
    Patent number: 8404811
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: March 26, 2013
    Assignee: Genentech, Inc.
    Inventors: Weilan Ye, Mark Dennis, Jill Fredrickson
  • Antibodies to EGFL7 and methods for their use
    Patent number: 8398976
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Anti-alpha5/beta1 antibody
    Patent number: 8350010
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: January 8, 2013
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
  • METHODS FOR INHIBITING OCULAR ANGIOGENESIS
    Publication number: 20120276083
    Abstract: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.
    Type: Application
    Filed: August 25, 2011
    Publication date: November 1, 2012
    Applicant: Genentech, Inc.
    Inventors: Harald J. Junge, Weilan Ye
  • Novel gene disruptions, compositions and methods relating thereto
    Publication number: 20120210450
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes.
    Type: Application
    Filed: April 8, 2011
    Publication date: August 16, 2012
    Inventors: Fred de Sauvage, Dorothy French, Lino Gonzalez, Asja Praetor, Weilan Ye, Katherin E. Combs, Zhiyong Ding, Allison Anne Byers Horner, Erin Marie Massey, Charles Montgomery, Laurie Jeanette Minze, Carolina Rangel, Tracy Ellen Willis Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Peter Vogel
  • COMBINATORIAL THERAPY
    Publication number: 20120195908
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Application
    Filed: June 28, 2011
    Publication date: August 2, 2012
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
  • NOVEL ANTIBODIES
    Publication number: 20120156129
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Application
    Filed: May 20, 2011
    Publication date: June 21, 2012
    Applicant: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • NOVEL ANTIBODIES
    Publication number: 20120148572
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Application
    Filed: May 20, 2011
    Publication date: June 14, 2012
    Applicant: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • Anti- ?5 ?1 antibodies and uses thereof
    Patent number: 8124740
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: February 28, 2012
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
    Publication number: 20120030776
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Application
    Filed: October 22, 2010
    Publication date: February 2, 2012
    Inventors: Katherin E. Combs, Ling Ling Culbertson, Frederic de Sauvage, Zhiyong Ding, Joel Edwards, Rosemary Girgis, Allison Anne Byers Horner, Harald Junge, Jagath Reddy Junutula, Erin Marie Massey, Dina Rebecca McLain, Charles Montgomery, Bobby Joe Payne, Heidi Phillips, Ni Nancy Qian, Carolina Rangel, Tracy Ellen Willis Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Peter Vogel, Weilan Ye
  • COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT
    Publication number: 20120003208
    Abstract: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
    Type: Application
    Filed: October 14, 2010
    Publication date: January 5, 2012
    Applicant: Genentech, Inc.
    Inventors: Ellen Filvaroff, Weilan Ye, Leon H. Parker, IV, Jo-Anne S. Hongo, Maike Schmidt
  • ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE
    Publication number: 20110200602
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 18, 2011
    Applicant: Genentech, Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Antibodies
    Patent number: 7973138
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: July 5, 2011
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • Novel Gene Disruptions, Compostitions and Methods Relating Thereto
    Publication number: 20110097330
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes.
    Type: Application
    Filed: February 27, 2006
    Publication date: April 28, 2011
    Applicants: Genentech, Inc., Lexicon Pharmaceuticals, Inc.
    Inventors: Allison Anne Byers Horner, Catherine Batac Clarke, Katherin E. Combs, Frederic J. de Sauvage, Joel Edwards, Paul Godowski, Deanna Grant Wilson, Wenhu Huang, Lorelei Diane Ketcherside, Erin Marie Massey, Charles Montgomery, Bobby Joe Payne, Andrew Peterson, Ni Nancy Qian, Jeffrey J. Schrick, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Colleen M. Viator, Peter Vogel, Weilan Ye, Jung-Hua Yeh, Zhiyong Ding
  • METHODS FOR INHIBITING ANGIOGENESIS USING EGFL8 ANTAGONISTS
    Publication number: 20110014194
    Abstract: The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.
    Type: Application
    Filed: January 14, 2009
    Publication date: January 20, 2011
    Inventors: Weilan Ye, Han Lu
  • HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
    Publication number: 20100285009
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Application
    Filed: May 7, 2010
    Publication date: November 11, 2010
    Applicant: Genentech, Inc.
    Inventors: Weilan Ye, Mark Dennis, Jill Fredrickson
  • NOVEL ANTI- Alpha 5 Beta 1 ANTIBODIES AND USES THEREOF
    Publication number: 20100260782
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: March 23, 2010
    Publication date: October 14, 2010
    Applicant: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE
    Publication number: 20100203041
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 16, 2007
    Publication date: August 12, 2010
    Applicant: Genentech , Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • METHODS FOR INHIBITING OCULAR ANGIOGENESIS
    Publication number: 20100129375
    Abstract: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 27, 2010
    Applicant: Genentech, Inc.
    Inventors: Harald J. Junge, Weilan Ye
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090313707
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 17, 2009
    Applicants: Genentech, Inc., Lexicon Pharamaceuticals, Inc.
    Inventors: Katherin E. Combs, Ling Ling Culbertson, Frederic J. de Sauvage, Zhiyong Ding, Joel Edwards, Rosemary Girgis, Allison A. B. Horner, Harald Junge, Jagath Reddy Junutula, Erin Marie Massey, Dina R. McLain, Charles Montgomery, Bobby Joe Payne, Heidi Phillips, Ni Nancy Qian, Carolina Rangel, Tracy E. W. Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Peter Vogel, Weilan Ye